Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Standard BioTools Inc.NASDAQ: LAB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $8.82M fell 2.1% year over year, ahead of the -5.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 53.6% from the prior quarter. Over 3 fiscal years it compounded at +25.8% a year.

Context

  • Stock-based compensation amounted to 34.7% of revenue in FY2025, up 16.5 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -2.1% holds above the trailing-twelve-month pace of -5.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.82M+53.6% QoQ
Last fiscal yearDec 2025
$29.61M-6.7% YoY
LTMMar 2026
$27.48M-5.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.1%——
1 year-6.7%——
3-year CAGR+25.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
29.61M USD
Year-over-year change
-6.7%
4-year CAGR
+16.5%

Stock-Based Compensation vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.7% is the 5th highest of 11, against a peer median of -11.4%.
  • Stock-based compensation amounts to 31.9% of revenue for LAB, versus a peer median of 7.4%.
LAB Competitors
Stock-Based Compensation for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$34.28M USD-12.0%+8.8%—
LABStandard BioTools Inc.LTM Mar 2026$27.48M USD-5.7%+25.8%31.9%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$25.13M USD-21.2%+61.0%12.1%
CTKBCytek Biosciences, Inc.LTM Mar 2026$22.82M USD-18.0%+14.0%11.2%
KIDSOrthoPediatrics Corp.LTM Mar 2026$17.9M USD+22.5%+38.6%7.4%
CBLLCeriBell, Inc.LTM Mar 2026$13.6M USD+94.2%+15.5%14.3%
BVSBioventus Inc.LTM Mar 2026$13.52M USD+36.9%-10.3%2.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M USD+26.4%-48.5%16.0%
AVNSAvanos Medical, Inc.LTM Mar 2026$12.5M USD-10.7%-7.5%1.7%
VREXVarex Imaging CorporationLTM Apr 2026$10.9M USD-28.8%+2.3%1.3%
SYSo-Young International Inc.LTM Dec 2025CN¥8.92M CNY-72.7%-41.0%0.6%
Peer median (excluding LAB) —-11.4%+5.6%7.4%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Depreciation & Amortization16.2M15.03M15.18M16.86M1.72M
Deferred Income Tax00000
Stock-Based Compensation16.1M14.88M13.12M31.73M29.61M
Change in Working Capital(18.01M)(12.35M)1.79M(12.08M)(44.98M)
Accounts Receivables6.73M1.06M(2.99M)8.97M(1.36M)
Inventory(4.78M)(8.47M)(4.91M)(9.88M)(11.52M)
Accounts Payables001.62M02.44M
Other Working Capital(19.95M)(4.95M)8.07M(11.17M)(34.53M)
Other Non-Cash Items886K83.17M1.28M(41.08M)14.2M
Operating Cash Flow(44.06M)(89.37M)(43.29M)(143.45M)(74.35M)
Capital Expenditures(13.26M)(3.83M)(2.83M)(8.36M)(8.3M)
Acquisitions (Net)000278.65M0
Purchases of Investments00(94.9M)0(140.93M)
Sales of Investments00117.96M0179M
Other Investing Activities1.32M(84.3M)092.88M(5M)
Investing Cash Flow(11.95M)(88.13M)20.24M363.17M24.77M
Debt Repayment9.5M18.16M(2.08M)(63.19M)0
Common Stock Issued00001.05M
Common Stock Repurchased(1.79M)(774K)(5.41M)(40.95M)0
Dividends Paid00000
Other Financing Activities8.25M213.37M827K1.53M(484K)
Financing Cash Flow15.96M230.76M(6.81M)(102.62M)570K
Effect of Forex Changes(21K)(404K)34K(785K)842K
Net Change in Cash(40.07M)52.86M(29.83M)116.32M(48.17M)
Free Cash Flow(57.33M)(93.2M)(46.12M)(151.81M)(82.65M)

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.